Oppenheimer raised the firm’s price target on Soleno Therapeutics to $65 from $59 and keeps an Outperform rating on the shares. Following its recent submission of DCCR’s new drug application for the treatment of Prader-Willi syndrome, Soleno is broadly progressing pre-commercial efforts in anticipation of U.S. approval and launch by Q2 2025, the firm says. Toward the end of this month, Oppenheimer expects the company to announce FDA acceptance of the NDA for review-and whether Priority Review is granted, which would put potential approval in late February.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Is SLNO a Buy, Before Earnings?
- These Stock Winners Are ‘Strong Buys’ With More Room Left to Run
- Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome
- Soleno Therapeutics submits NDA for DCCR extended-release tablets
- Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)